RESPONSE UNDER 37 CFR 1.116
EXPEDITED PROCEDURE
EXAMINING GROUP 1643

DO NOT ENTER: /D.B./

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Attorney Docket No.:

DEX0499US.NP

Inventors:

Fan et al.

Serial No.:

10/593,799

Filing Date:

August 6, 2007

Examiner:

Blanchard, David J.

Customer No.:

32800

Group Art Unit:

1643

Confirmation No.:

2565

Title:

LNG105 Antibody Composition and Methods of Use, and Use of LNG105 to Assess Lung Cancer Risk

Electronically Submitted via EFS-Web

Date: September 7, 2010

I hereby certify that this paper is being electronically submitted on the date indicated above to the Commissioner for Patents, U.S. Patent &

Trademark Office,

Typed Name: Kathleen A. Tyrrell, Reg. No. 38,350

Commissioner for Patents

U.S. Patent & Trademark Office

Dear Sir:

## Reply under 37 C.F.R. 1.116

This is a reply to the Final Rejection mailed September 4, 2010 setting a three (3) month statutory period for response. Please enter the following amendments and remarks into the record.

Amendments to the claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks begin on page 6.